Imperial College London
Portrait Picture

ProfessorIainMcNeish

Faculty of Medicine, Department of Surgery & Cancer

Chair in Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2185i.mcneish Website

 
 
//

Assistant

 

Ms Sophie Lions +44 (0)20 7594 2792

 
//

Location

 

G036Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@inproceedings{Christopoulou:2019:10.1136/ijgc-2019-ESGO.179,
author = {Christopoulou, A and Marme, F and Oaknin, A and Lorusso, D and Safra, T and Lindahl, G and Chudecka-Glaz, A and Ciuleanu, T and Collins, DC and Demirkiran, F and Lifrenko, I and Van, Gorp T and Coleman, RL and Fujiwara, K and Oza, AM and Westin, SN and O'Malley, DM and Herzog, TJ and Eskander, R and Wilson, M and Argire, S and Grechko, N and McNeish, IA and Monk, BJ and Kristeleit, RS},
doi = {10.1136/ijgc-2019-ESGO.179},
pages = {A130--A131},
publisher = {BMJ PUBLISHING GROUP},
title = {ATHENA (GOG-3020/ENGOT-OV45; EUDRACT 2017-004557-17; NCT03522246): A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR RUCAPARIB + THE PD-1 INHIBITOR NIVOLUMAB FOLLOWING FRONTLINE PLATINUM-BASED CHEMOTHERAPY IN OVARIAN CANCER (OC)},
url = {http://dx.doi.org/10.1136/ijgc-2019-ESGO.179},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - CPAPER
AU  - Christopoulou,A
AU  - Marme,F
AU  - Oaknin,A
AU  - Lorusso,D
AU  - Safra,T
AU  - Lindahl,G
AU  - Chudecka-Glaz,A
AU  - Ciuleanu,T
AU  - Collins,DC
AU  - Demirkiran,F
AU  - Lifrenko,I
AU  - Van,Gorp T
AU  - Coleman,RL
AU  - Fujiwara,K
AU  - Oza,AM
AU  - Westin,SN
AU  - O'Malley,DM
AU  - Herzog,TJ
AU  - Eskander,R
AU  - Wilson,M
AU  - Argire,S
AU  - Grechko,N
AU  - McNeish,IA
AU  - Monk,BJ
AU  - Kristeleit,RS
DO  - 10.1136/ijgc-2019-ESGO.179
EP  - 131
PB  - BMJ PUBLISHING GROUP
PY  - 2019///
SN  - 1048-891X
SP  - 130
TI  - ATHENA (GOG-3020/ENGOT-OV45; EUDRACT 2017-004557-17; NCT03522246): A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR RUCAPARIB + THE PD-1 INHIBITOR NIVOLUMAB FOLLOWING FRONTLINE PLATINUM-BASED CHEMOTHERAPY IN OVARIAN CANCER (OC)
UR  - http://dx.doi.org/10.1136/ijgc-2019-ESGO.179
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000523502500179&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
ER  -
Download